VESPA
13.2.2024 15:01:32 CET | Business Wire | Press release
Vespa, supplier of the leading platform for applications that leverage AI and data online at scale, today announced it has earned recognition as a leader and forward mover in the GigaOm Sonar for Vector Databases.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240213670564/en/
GigaOm Sonar Reports evaluate technology that is new, interesting, and attractive but poses intrinsic risk when it comes to enterprise adoption. These reports give you the right information at the right time to help plan your strategy. Vespa is positioned as a Leader and Forward Mover in GigaOm's latest report on vector databases. (Graphic: Business Wire)
The research cites Vespa as a platform leader “because of its widespread embedding flexibility, rapid time for updating, and hybrid search capabilities–with neural network rankings. These are critical to maximizing the ROI for vector similarity search engines.”
Andrew Brust, Analyst, GigaOm: “Interest in the vector database market is surging as industries seek advanced AI to manage vast unstructured data. Vespa is well placed in this market with strengths that include model versatility, search flexibility and real-time capabilities.”
Daniel Doro, Director of Engineering, Search, Spotify: “As a reliable and scalable solution, Vespa has been instrumental in enabling Search at Spotify. We look forward to continuing our work with the Vespa team and enabling innovation that will enhance the experience for Spotify listeners.”
Jungwon Byun, COO & Cofounder, Elicit: “Vespa is a battle-tested platform that allows us to integrate keyword and vector search seamlessly. It forms a key part of our AI research solution, guaranteeing precision and rapidity in streamlining research processes. We highly recommend Vespa for its reliability and efficiency.”
Jon Bratseth, CEO and Founder, Vespa: “We are pleased to be recognized as a leader in an emerging, highly relevant, and rapidly growing market. AI is getting significant attention for its role in solving today's data challenges found in eCommerce, digital media, financial services and other industries. Vespa enables organizations to realize this opportunity. GigaOm brings clarity to this crowded and hype laden market.”
In October 2023, Vespa was spun out from Yahoo as an independent company, although the technology has existed for over a decade. Yahoo remains a key investor with Vespa technology underpinning approximately 150 applications that are integral to Yahoo’s operations.
The GigaOm Sonar for Vector Databases can be downloaded here:
https://content.vespa.ai/gigaom-report-2024
About Vespa
Vespa is a platform for applications which leverage AI and data to deliver experiences to end users online in real time, such as search, recommendation, personalization, and retrieval-augmented generation (RAG). Vespa automatically organizes data, inference and logic to allow applications to work with any amount of data, queries, and is available both as a managed service and as open source.
About Elicit
Elicit is the first AI research assistant using language models to automate research workflows like literature review. Over 250,000 researchers in leading academic and industry labs around the world use Elicit every month to summarize papers and extract insights at scale.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240213670564/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wyss Geneva Steps Into Its Next Chapter11.6.2026 13:33:00 CEST | Press release
Dr. Tracy Laabs named Director; Prof. Dr. Erwin Böttinger honored for his transformative leadership The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simult
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 13:24:00 CEST | Press release
Nearly two-thirds of patients aged 80+ treated with BRUKINSA remained progression-free at six years, despite advanced age and high-risk featuresNew European patient research reveals safety, disease severity, and effectiveness are the top drivers for first-line CLL treatment decisions – not time on therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D.,
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 13:00:00 CEST | Press release
Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib Safety profile was consistent with previous studies with no new safety signals identified Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrate
Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 13:00:00 CEST | Press release
Transaction adds 31 CLOs and more than $5 billion of AUM, strengthening Clearlake Credit’s position in liquid credit Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction
L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 12:30:00 CEST | Press release
Partnership brings together LTTS’ expertise in its Sustainability segment and the Databricks platform to accelerate Engineering Intelligence across industrial operations. L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom